Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers


The GSTP1, GSTM1, and GSTT1 detoxification genes all have functional polymorphisms that are common in the general population. A single study of 320 BRCA1/2 carriers previously assessed their effect in BRCA1 or BRCA2 mutation carriers. This study showed no evidence for altered risk of breast cancer for individuals with the GSTT1 and GSTM1 deletion variants, but did report that the GSTP1 Ile105Val (rs1695) variant was associated with increased breast cancer risk in carriers. We investigated the association between these three GST polymorphisms and breast cancer risk using existing data from 718 women BRCA1 and BRCA2 mutation carriers from Australia, the UK, Canada, and the USA. Data were analyzed within a proportional hazards framework using Cox regression. There was no evidence to show that any of the polymorphisms modified disease risk for BRCA1 or BRCA2 carriers, and there was no evidence for heterogeneity between sites. These results support the need for replication studies to confirm or refute hypothesis-generating studies.

This is a preview of subscription content, log in to check access.


  1. 1.

    Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130

  2. 2.

    Begg CB, Haile RW, Borg A, Malone KE, Concannon P, Thomas DC, Langholz B, Bernstein L, Olsen JH, Lynch CF et al (2008) Variation of breast cancer risk among BRCA1/2 carriers. JAMA 299(2):194–201

  3. 3.

    Simchoni S, Friedman E, Kaufman B, Gershoni-Baruch R, Orr-Urtreger A, Kedar-Barnes I, Shiri-Sverdlov R, Dagan E, Tsabari S, Shohat M et al (2006) Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. Proc Natl Acad Sci USA 103(10):3770–3774

  4. 4.

    Antoniou AC, Sinilnikova OM, Simard J, Leone M, Dumont M, Neuhausen SL, Struewing JP, Stoppa-Lyonnet D, Barjhoux L, Hughes DJ et al (2007) RAD51 135G→C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet 81(6):1186–1200

  5. 5.

    Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N et al (2008) Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 82(4):937–948

  6. 6.

    Antoniou AC, Sinilnikova OM, McGuffog L, Healey S, Nevanlinna H, Heikkinen T, Simard J, Spurdle AB, Beesley J, Chen X et al (2009) Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 18(22):4442–4456

  7. 7.

    Adang AE, Meyer DJ, Brussee J, Van der Gen A, Ketterer B, Mulder GJ (1989) Interaction of rat glutathione S-transferases 7–7 and 8–8 with gamma-glutamyl- or glycyl-modified glutathione analogues. Biochem J 264(3):759–764

  8. 8.

    Hengstler JG, Arand M, Herrero ME, Oesch F (1998) Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility. Recent Results Cancer Res 154:47–85

  9. 9.

    Strange RC, Fryer AA (1999) The glutathione S-transferases: influence of polymorphism on cancer susceptibility. In: Vineis P (ed) Metabolic polymorphisms and susceptibility to cancer, vol 148. IARC Scientific Publications, Lyon, pp 231–249

  10. 10.

    Board PG (1981) Biochemical genetics of glutathione-S-transferase in man. Am J Hum Genet 33(1):36–43

  11. 11.

    Pemble S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt HM, Ketterer B, Taylor JB (1994) Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 300(Pt 1):271–276

  12. 12.

    Seidegard J, Vorachek WR, Pero RW, Pearson WR (1988) Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci USA 85(19):7293–7297

  13. 13.

    Ali Osman F, Akande O, Antoun G, Mao JX, Buolamwini J (1997) Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem 272(15):10004–10012

  14. 14.

    Johansson AS, Stenberg G, Widersten M, Mannervik B (1998) Structure-activity relationships and thermal stability of human glutathione transferase P1-1 governed by the H-site residue 105. J Mol Biol 278(3):687–698

  15. 15.

    Zimniak P, Nanduri B, Pikula S, Bandorowicz Pikula J, Singhal SS, Srivastava SK, Awasthi S, Awasthi YC (1994) Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur J Biochem 224(3):893–899

  16. 16.

    Bugano DD, Conforti-Froes N, Yamaguchi NH, Baracat EC (2008) Genetic polymorphisms, the metabolism of estrogens and breast cancer: a review. Eur J Gynaecol Oncol 29(4):313–320

  17. 17.

    Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, Tardon A, Serra C, Carrato A, Garcia-Closas R et al (2005) NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366(9486):649–659

  18. 18.

    Sampaio AC, Morari EC, Bufalo NE, Leite JL, Lima CS, Ward LS (2009) Lack of influence of glutathione S-transferase genotype profile on cancer susceptibility in smokers and nonsmokers. Med Sci Monit 15(1):CR10–CR15

  19. 19.

    Sergentanis TN, Economopoulos KP (2009) GSTT1 and GSTP1 polymorphisms and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. doi:10.1007/s10549-009-520-0

  20. 20.

    Kadouri L, Kote-Jarai Z, Hubert A, Baras M, Abeliovich D, Hamburger T, Peretz T, Eeles RA (2008) Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers. Br J Cancer 98(12):2006–2010

  21. 21.

    Kanetsky PA, Holmes R, Walker A, Najarian D, Swoyer J, Guerry D, Halpern A, Rebbeck TR (2001) Interaction of glutathione S-transferase M1 and T1 genotypes and malignant melanoma. Cancer Epidemiol Biomarkers Prev 10(5):509–513

  22. 22.

    Spurdle AB, Webb PM, Purdie DM, Chen X, Green A, Chenevix-Trench G (2001) Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype. Carcinogenesis 22(1):67–72

  23. 23.

    Huber PJ (1967) The behaviour of maximum likelihood estimates under non-standard conditions. In: Fifth Berkeley symposium in mathematical statistics and probability: 1967; Berkeley, California. University of California Press, pp 221–233

  24. 24.

    Antoniou AC, Goldgar DE, Andrieu N, Chang-Claude J, Brohet R, Rookus MA, Easton DF (2005) A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genet Epidemiol 29(1):1–11

  25. 25.

    Parl F (2009) A need for true GSTM1 and GSTT1 genotyping. Cancer Epidemiol Biomarkers Prev 18(10):2793

Download references


kConFab—The Kathleen Cuningham Consortium for Research into Familial Breast Cancer

We wish to thank Heather Thorne, Eveline Niedermayr, all the kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study (funded by NHMRC grants 145684, 288704, and 454508) for their contributions to this resource, and the many families who contribute to kConFab. The kConFab is supported by grants from the National Breast Cancer Foundation, the National Health and Medical Research Council (NHMRC), and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. ABS is an NHMRC Senior Research Fellow, and GC-T is an NHMRC Senior Principal Research Fellow.

Epidemiological study of BRCA1 and BRCA2 mutation carriers (EMBRACE)

DE is the PI of the study. DE, SP, and MC are funded by Cancer Research, UK Grants C1287/A10118 and C1287/A8874. EMBRACE Collaborating Centers are: Coordinating Centre, Cambridge: Susan Peock, Margaret Cook, Clare Oliver, Debra Frost; North of Scotland Regional Genetics Service, Aberdeen: Helen Gregory, Zosia Miedzybrodzka; Northern Ireland Regional Genetics Service, Belfast: Patrick Morrison; West Midlands Regional Clinical Genetics Service, Birmingham: Trevor Cole, Carole McKeown, Amy Taylor; South West Regional Genetics Service, Bristol: Alan Donaldson; East Anglian Regional Genetics Service, Cambridge: Joan Paterson; Medical Genetics Services for Wales, Cardiff: Alexandra Murray, Mark Rogers, Emma McCann; St James’s Hospital, Dublin & National Centre for Medical Genetics, Dublin: John Kennedy, David Barton; South East of Scotland Regional Genetics Service, Edinburgh: Mary Porteous; Peninsula Clinical Genetics Service. Exeter: Carole Brewer, Emma Kivuva, Anne Searle, Selina Goodman; West of Scotland Regional Genetics Service, Glasgow: Rosemarie Davidson, Victoria Murday, Nicola Bradshaw, Lesley Snadden, Mark Longmuir, Catherine Watt; South East Thames Regional Genetics Service, Guys Hospital London: Louise Izatt, Gabriella Pichert, Caroline Langman. North West Thames Regional Genetics Service. Harrow: Huw Dorkins; Leicestershire Clinical Genetics Service; Leicester: Julian Barwell; Yorkshire Regional Genetics Service, Leeds: Carol Chu, Tim Bishop, Julie Miller; Merseyside & Cheshire Clinical Genetics Service. Liverpool: Ian Ellis; Manchester Regional Genetics Service, Manchester: D Gareth Evans, Fiona Lalloo, Felicity Holt; North East Thames Regional Genetics Service, NE Thames: Alison Male, Anne Robinson. Nottingham Centre for Medical Genetics, Nottingham: Carol Gardiner; Northern Clinical Genetics Service, Newcastle: Fiona Douglas, Oonagh Claber; Oxford Regional Genetics Service, Oxford: Lisa Walker, Diane McLeod; The Institute of Cancer Research and Royal Marsden NHS Foundation Trust: Ros Eeles, Susan Shanley, Nazneen Rahman, Richard Houlston, Elizabeth Bancroft, Lucia D’Mello, Elizabeth Page, Audrey Ardern-Jones, Anita Mitra; North Trent Clinical Genetics Service, Sheffield: Jackie Cook, Oliver Quarrell, Cathryn Bardsley; South West Thames Regional Genetics Service, London: Shirley Hodgson, Sheila Goff, Glen Brice, Lizzie Winchester; Wessex Clinical Genetics Service; Princess Anne Hospital, Southampton: Diana Eccles, Anneke Lucassen, Gillian Crawford, Emma Tyler, Donna McBride. ACA is a Cancer Research UK Senior Cancer Research Fellow. CIMBA data management is supported by Cancer Research UK. The kConFab and EMBRACE genotyping was supported by an NHMRC Programme grant to GCT. MAGIC data collection and analysis was supported by R01-CA102776 to TRR.

Interdisciplinary Health Research International Team on Breast Cancer Susceptibility (INHERIT BRCAs)

Jacques Simard, Francine Durocher, Rachel Laframboise, Marie Plante, Centre Hospitalier Universitaire de Québec & Laval University, Québec, Canada; Peter Bridge, Jilian Parboosingh, Molecular Diagnostic Laboratory, Alberta Children’s Hospital, Calgary, Canada; Jocelyne Chiquette, Hôpital du Saint-Sacrement, Québec, Canada; Bernard Lespérance, Hôpital du Sacré-Cœur de Montréal, Montréal, Canada. Jacques Simard- J.S. is Chairholder of the Canada Research Chair in Oncogenetics. This study was supported by the Canadian Institutes of Health Research for the “CIHR Team in Familial Risks of Breast Cancer” program.

Modifiers and Genetics in Cancer (MAGIC)

This work was supported by the NIH grants R01-CA102776 and R01-CA083855 (to TRR). The MAGIC Consortium includes the following centers and individuals: Baylor- Charles A. Sammons Cancer Center (Joanne L, Blum, M.D. Ph.D.; Becky Althaus, R.N., C.G.C.; Gaby Ethington), Baylor College of Medicine (Claire Noll; Sharon Plon, M.D., Ph.D.), Beth Israel Deaconess Medical Center (Nadine Tung, M.D.), City of Hope National Medical Center (Sharon Sand; Jeffrey N. Weitzel, M.D.), Creighton University (Carrie Snyder, B.A.; Henry T. Lynch, M.D.; Patrice Watson, Ph.D.), Dana-Farber Cancer Institute (Kathryn Stoeckert; Judy E. Garber, M.D., M.P.H.), Duke University (Sydnee Crankshaw; Joellen Schildkraut, Ph.D.), Evanston Northwestern Healthcare Center for Medical Genetics (Suzanne M. O’Neill, Ph.D.; Christina Selkirk; Wendy S. Rubinstein, M.D., Ph.D.), Fox Chase Cancer Center (Mary B. Daly, M.D., Ph.D.; Andrew Godwin, Ph.D.), Queensland Institute of Medical Research (Georgia Chenevix-Trench), Georgetown University (Claudine Isaacs, M.D.), Jonsson Comprehensive Cancer Center at the University of California-Los Angeles (Joyce Seldon; Patricia A. Ganz, M.D.), Mayo Clinic College of Medicine (Linda Wadum; Fergus Couch, Ph.D.), University of Chicago (Shelly Cummings; Olufunmilayo Olopade, M.D.), University of California-Irvine (Susan L. Neuhausen, Ph.D.; Linda Steele), University of Pennsylvania Health System (Susan Domchek, M.D.; Katherine Nathanson M.D.; Tara Friebel, M.P.H.; Timothy Rebbeck, Ph.D.), University of Texas Southwestern (Gail Tomlinson, M.D.), University of Vienna (Christian Singer, M.D.), and Women’s College Hospital (Steven A. Narod, M.D.).

Author information

Correspondence to Georgia Chenevix-Trench.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Spurdle, A.B., Fahey, P., Chen, X. et al. Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 122, 281–285 (2010).

Download citation


  • GST polymorphisms
  • BRCA1
  • BRCA2
  • Modifier gene